Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Fourth quarter surgical revenue of $123 million increased 34% against a tough 49% previous year comparison with strong contribution from our entire portfolio |
| And so you will start to see that in '25, and that's a unique opportunity for us |
| And so your ability to literally manipulate both those at the same time in a navigated way is fantastic |
| These better outcomes will drive a better day |
| So, I think we're very excited about the opportunity |
| So, the whole Insight, the Insight portfolio is -- we are super excited about it |
| But if things of that nature that I think you're going to see a lot of -- we also have a keep expandable TLIF implant that's going to be excellent |
| The profitability progress we have and will continue to make, along with a well-funded balance sheet, position us to progress toward cash flow breakeven in 2025 and self-funded growth thereafter |
| It presented us with an unprecedented competitive opportunity, one that we ceased equipping our balance sheet of cash to invest in the high-return revenue-generating assets that will fuel growth in the years to come |
| But I would characterize 2023 as a very good year |
| The degree of progress that we have delivered and the drivers of expected leverage contributing as planned, give us great confidence in continued operating profitability improvement |
| We expect these dynamics to drive mid-single-digit percent growth in average revenue per case for the full year 2024 |
| The increase in procedural complexity and increasing biologics [Indiscernible] are also tailwinds |
| We expect these dynamics to fuel up 20% procedure volume growth for the full year 2024 |
| Each new surgeon relationship that we established typically unlocks a multiyear utilization growth opportunity |
| Our procedures build surgeon confidence, which inspires loyalty and empower surgeons to work up the procedural complexity curve, both of which increased utilization |
| Surgeon user growth has consistently been strong, growing 27% in 2023 |
| That positions us well to achieve our long-term profitability and free cash flow commitments |
| As sales growth powers leverage across our business, we expect to achieve continued solid profitability progress |
| Consistent with our January pre-release, we expect continued portfolio-wide momentum to drive full year 2024 total revenue growth of 23% to approximate $595 million |
| We demonstrated an ability to grow the top line and significantly expand profitability margins, while also investing in the future growth of the business |
| The consistent adjusted EBITDA margin expansion that we are driving underscores our confidence in achieving the long-term profitability goals we've committed to |
| Additionally, surgical revenue mix and operations efficiencies drove margin improvement in the quarter |
| The year-over-year increase was primarily driven by improved EOS gross margin, which is benefiting from the execution as we improve service operations and for pricing initiatives |
| Fourth quarter adjusted EBITDA under the previous non-GAAP definition would have been $6 million, drop-through on incremental revenue dollars of 28% and strong performance compared to the $5 million expectations implied by previous guidance |
| is also benefiting EOS ASPs |
| EOS, of $59 million grew 24% over full year 2022 on continued strong interest in the technology, a geographical mix shift towards the U.S |
| Average revenue per case grew 7%, driven by increased mix of lateral surgeries and expanding biologics attach rate and greater case complexity |
| Average revenue per case grew 4% year-over-year, driven by increased mix of lateral surgeries and expanding biologics attach rate and greater case complexity |
| That has an acceleration compared to the third quarter procedural volume growth of 24% |
| Statement |
|---|
| The revenue growth that recent cervical innovation is delivering is a slight headwind to average revenue per case as cervical cases feature a lower-than-average ASP |
| But people still have side pain because of plexopathy because what they're doing is retracting the Plexus to them |
| We are in this for the long haul, clearly, and we can't be more excited about the momentum that was created in a great year in 2023 |
| And so my concern always is kind of the over enthusiastic view on someone who just comes over |
| And so we can't be more excited about that |
| Increasing mix of cervical surgeries is offsetting those tailwinds to some degree |
| What I think so often happens is that revenue is a lag indicator |
| The increasing mix of cervical surgeries is offsetting those tailwinds to some degree |
| And so when you ask kind of is there an impediment to long-term growth, there really isn't |
| Full year 2023 adjusted EBITDA under the previous non-GAAP definition would have been $4 million, reflecting drop-through of 25% on incremental revenue dollars and ahead of the $3 million that we guided to last quarter |
| And it's a lag indicator or bringing people over getting access to the hospitals, getting the surgeons familiar with the goods, but there's a lot that goes into it |
| Pat Miles That was a tough one, Brooks |
| We're in this for the long haul, and I can't be more excited about what we're building |
| And so the immediacy of the influence is somewhat muted |
| And so that's why we always say revenue is a lag indicated to the work that we've done 18 to 24 before |
| We've really never been more enthusiastic with regard to the status of the marketplace in general |
| That overhaul generated material, but non-cash excess and obsolete inventory charges, or E&O, as legacy product portfolio were obviated and discontinued |
| And you've talked about being under-indexed in certain U.S |
Please consider a small donation if you think this website provides you with relevant information